SG11201909252XA - Fgfr3 binding molecules - Google Patents
Fgfr3 binding moleculesInfo
- Publication number
- SG11201909252XA SG11201909252XA SG11201909252XA SG11201909252XA SG 11201909252X A SG11201909252X A SG 11201909252XA SG 11201909252X A SG11201909252X A SG 11201909252XA SG 11201909252X A SG11201909252X A SG 11201909252XA
- Authority
- SG
- Singapore
- Prior art keywords
- amino acid
- seq
- archimedesweg
- leiden
- acid sequence
- Prior art date
Links
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 17
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 2
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 abstract 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000001708 Protein Isoforms Human genes 0.000 abstract 1
- 108010029485 Protein Isoforms Proteins 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
- C12Y207/10002—Non-specific protein-tyrosine kinase (2.7.10.2), i.e. spleen tyrosine kinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
Abstract
1 O O GC 1-1 00 O 1-1 N O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo OH H 100 0111010110111110 oimIE (10) International Publication Number WO 2018/185050 Al (51) International Patent Classification: CO7K 16/28 (2006.01) CO7K 14/705 (2006.01) (21) International Application Number: PCT/EP2018/058390 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164482.6 03 April 2017 (03.04.2017) EP (71) Applicant: COVAGEN AG [CH/CH]; Gubelstrasse 34, 6300 Zug (CH). (72) Inventors: SILACCI MELKKO, Michaela; Archimedesweg 4-6, 2333 CN Leiden (NL). WOODS, Richard; Archimedesweg 4-6, 2333 CN Leiden (NL). HENNE, Patricia; Archimedesweg 4-6, 2333 CN Leiden (NL). ZUBLER, Barbara; Archimedesweg 4-6, 2333 CN Leiden (NL). KAGE, Elena; Archimedesweg 4-6, 2333 CN Leiden (NL). GRABULOVSKI, Dragan; Archimedesweg 4-6, 2333 CN Leiden (NL). BERTSCHINGER, Julian; Archimedesweg 4-6, 2333 CN Leiden (NL). (74) Agent: VERHAGE, Richard, A et al.; Archimedesweg 4-6, 2333 CN Leiden (NL). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: FGFR3 BINDING MOLECULES (57) : The present invention relates to a polypeptide binding to fibroblast growth factor receptor 3 iso forms 3b and 3c (FGFR3b and FGFR3c), wherein the polypeptide comprises an amino acid sequence selected from the group consisting of: (a) GVTLFVALYDYEVYGPTPMLSFHKGEKFQIUX 1)(X2X3) (X 4 )GPYWEARSL(X)TGETG(X)IPSNYVAPVDSIQ (SEQ ID 5 6 NO: 1), wherein amino acid positions (X) to (X) may be any amino acid sequence; (b) an amino acid sequence which is at least 95% 1 6 identical to the amino acid sequence of (a), wherein the identity determination excludes amino acid positions (X 1 ) to (X) and provided 6 that the amino acid sequence EVYGPTPM (SEQ ID NO: 2) in amino acid positions 12 to 19 of SEQ ID NO: 1 is conserved and the amino acids P and Yin amino acid positions 37 and 38 of SEQ ID NO: 1 are conserved; (c) GVTLFVALYDYEVMSTTALSFHKGEKF QILSQSPHGQYWEARSLTTGETG(X 6 )IPSNYVAPVDSIQ (SEQ ID NO: 19), wherein the amino acid position (X 6 ) may be any amino acid; and (d) an amino acid sequence which is at least 95% identical to the amino acid sequence of (c), wherein the identity determination excludes amino acid position (X 6 ) and provided that the amino acid sequences EVMSTTA (SEQ ID NO: 20) in amino acid positions 12 to 18 of SEQ ID NO: 19 and SQSPH (SEQ ID NO: 21) in amino acid positions 31 to 35 of SEQ ID NO: 19 are conserved and the amino acids Q and Y in amino acid positions 37 and 38 of SEQ ID NO: 19 are conserved.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17164482 | 2017-04-03 | ||
PCT/EP2018/058390 WO2018185050A1 (en) | 2017-04-03 | 2018-04-03 | Fgfr3 binding molecules |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201909252XA true SG11201909252XA (en) | 2019-11-28 |
Family
ID=58606015
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201909252X SG11201909252XA (en) | 2017-04-03 | 2018-04-03 | Fgfr3 binding molecules |
Country Status (19)
Country | Link |
---|---|
US (2) | US10722589B2 (en) |
EP (1) | EP3606953B1 (en) |
JP (1) | JP6840907B2 (en) |
KR (1) | KR20190137831A (en) |
CN (1) | CN110536904A (en) |
AU (1) | AU2018247801B2 (en) |
BR (1) | BR112019019666A2 (en) |
CA (1) | CA3056362A1 (en) |
DK (1) | DK3606953T3 (en) |
EA (1) | EA201992349A1 (en) |
ES (1) | ES2883377T3 (en) |
HR (1) | HRP20211096T1 (en) |
HU (1) | HUE054869T2 (en) |
IL (1) | IL269752B (en) |
LT (1) | LT3606953T (en) |
NZ (1) | NZ757365A (en) |
SG (1) | SG11201909252XA (en) |
SI (1) | SI3606953T1 (en) |
WO (1) | WO2018185050A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3861117A4 (en) * | 2018-10-02 | 2023-01-11 | Mitsubishi Tanabe Pharma Corporation | Bi-specific binding agents targeting syndecan-1 and fibroblast growth factor receptor |
CN114716548A (en) * | 2021-01-05 | 2022-07-08 | (株)爱恩德生物 | anti-FGFR 3 antibodies and uses thereof |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
AU631545B2 (en) | 1988-04-15 | 1992-12-03 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
CA2050918A1 (en) | 1990-01-12 | 1991-07-13 | Raju Kucherlapati | Generation of xenogeneic antibodies |
ATE381614T1 (en) | 1992-07-24 | 2008-01-15 | Amgen Fremont Inc | FORMATION OF XENOGENE ANTIBODIES |
KR100654645B1 (en) | 1995-04-27 | 2007-04-04 | 아브게닉스, 인크. | Human Antibodies from Immunized Genomous |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
WO2002102854A2 (en) | 2001-06-20 | 2002-12-27 | Morphosys Ag | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
IL156495A0 (en) | 2003-06-17 | 2004-01-04 | Prochon Biotech Ltd | Use of fgfr3 antagonists for treating t cell mediated diseases |
WO2006048877A2 (en) | 2004-11-04 | 2006-05-11 | Fibron Limited | Treatment of b-cell malignancies with fgfr3 inhibitors |
US8101721B2 (en) | 2006-06-15 | 2012-01-24 | Fibron Ltd. | Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof |
EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
US8187601B2 (en) | 2008-07-01 | 2012-05-29 | Aveo Pharmaceuticals, Inc. | Fibroblast growth factor receptor 3 (FGFR3) binding proteins |
MX345909B (en) * | 2009-03-25 | 2017-02-22 | Genentech Inc | Anti-fgfr3 antibodies and methods using same. |
CA2772162C (en) | 2009-08-27 | 2018-05-22 | Covagen Ag | Anti-il-17a fynomers and medical uses thereof |
KR20140135251A (en) | 2012-03-16 | 2014-11-25 | 코바겐 아게 | Novel binding molecules with antitumoral activity |
EP2711016A1 (en) | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
MX2015014608A (en) * | 2013-04-19 | 2016-03-03 | Covagen Ag | Novel bispecific binding molecules with antitumoral activity. |
TWI674274B (en) | 2014-03-17 | 2019-10-11 | 日商田邊三菱製藥股份有限公司 | Antibody-fynomer conjugates |
-
2018
- 2018-04-02 US US15/943,137 patent/US10722589B2/en active Active
- 2018-04-03 BR BR112019019666A patent/BR112019019666A2/en unknown
- 2018-04-03 JP JP2019569749A patent/JP6840907B2/en active Active
- 2018-04-03 CN CN201880022181.4A patent/CN110536904A/en active Pending
- 2018-04-03 HU HUE18714525A patent/HUE054869T2/en unknown
- 2018-04-03 CA CA3056362A patent/CA3056362A1/en active Pending
- 2018-04-03 DK DK18714525.5T patent/DK3606953T3/en active
- 2018-04-03 WO PCT/EP2018/058390 patent/WO2018185050A1/en unknown
- 2018-04-03 EP EP18714525.5A patent/EP3606953B1/en active Active
- 2018-04-03 SG SG11201909252X patent/SG11201909252XA/en unknown
- 2018-04-03 SI SI201830352T patent/SI3606953T1/en unknown
- 2018-04-03 KR KR1020197031642A patent/KR20190137831A/en not_active Application Discontinuation
- 2018-04-03 NZ NZ757365A patent/NZ757365A/en not_active IP Right Cessation
- 2018-04-03 EA EA201992349A patent/EA201992349A1/en unknown
- 2018-04-03 ES ES18714525T patent/ES2883377T3/en active Active
- 2018-04-03 AU AU2018247801A patent/AU2018247801B2/en not_active Ceased
- 2018-04-03 LT LTEP18714525.5T patent/LT3606953T/en unknown
-
2019
- 2019-10-02 IL IL269752A patent/IL269752B/en active IP Right Grant
-
2020
- 2020-06-15 US US16/901,160 patent/US11351267B2/en active Active
-
2021
- 2021-07-09 HR HRP20211096TT patent/HRP20211096T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
DK3606953T3 (en) | 2021-08-16 |
JP6840907B2 (en) | 2021-03-10 |
US20180280527A1 (en) | 2018-10-04 |
CA3056362A1 (en) | 2018-10-11 |
WO2018185050A1 (en) | 2018-10-11 |
NZ757365A (en) | 2022-07-01 |
EA201992349A1 (en) | 2020-02-17 |
JP2020518279A (en) | 2020-06-25 |
EP3606953A1 (en) | 2020-02-12 |
US11351267B2 (en) | 2022-06-07 |
HUE054869T2 (en) | 2021-10-28 |
SI3606953T1 (en) | 2021-10-29 |
BR112019019666A2 (en) | 2020-04-22 |
US10722589B2 (en) | 2020-07-28 |
LT3606953T (en) | 2021-08-10 |
US20200345859A1 (en) | 2020-11-05 |
AU2018247801A1 (en) | 2019-09-26 |
CN110536904A (en) | 2019-12-03 |
ES2883377T3 (en) | 2021-12-07 |
IL269752B (en) | 2020-03-31 |
HRP20211096T1 (en) | 2021-10-15 |
EP3606953B1 (en) | 2021-05-26 |
KR20190137831A (en) | 2019-12-11 |
AU2018247801B2 (en) | 2020-02-20 |
IL269752A (en) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201807912SA (en) | Vaccine against rsv | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201806963PA (en) | Functional mung bean-derived compositions | |
SG11201909918XA (en) | Compositions and methods for improving sample identification in indexed nucleic acid libraries | |
SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804373VA (en) | Compositions and methods for immunooncology | |
SG11201804161VA (en) | Compositions comprising bacterial strains | |
SG11201907402SA (en) | Population-based immunogenic peptide identification platform | |
SG11201803958WA (en) | Nucleic acids encoding repetitive amino acid sequences rich in proline and alanine residues that have low repetitive nucleotide sequences | |
SG11201404836QA (en) | Long-acting coagulation factors and methods of producing same | |
SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
SG11201909011PA (en) | Niraparib compositions | |
SG11201906271QA (en) | Potent and short promoter for expression of heterologous genes | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201900845YA (en) | Uses of il-13 antagonists for treating atopic dermatitis | |
SG11201908784TA (en) | Improved antigen binding receptor formats | |
SG11201807134RA (en) | Transposon system and methods of use | |
SG11201809903WA (en) | Method for purification and activation of botulinum neurotoxin | |
SG11201900573UA (en) | Methods of purifying fc-containing proteins | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same |